FLAG Therapeutics, Inc., founded in 2013 and headquartered in Raleigh, North Carolina,  is an early-stage oncology company focused on the development of therapies based on two investigational product platforms--the Anti-angiogenic/Anti-tubulin (AA/AT) platform and Facilitative Transporter Anti-cancer (FTAC) platform.   

These two platforms are comprised of thousands of investigational water-soluble small molecule compounds designed to target and destroy cancer cells through well-established mechanisms of action. Preclinical studies suggest that these investigational compounds hold the potential to treat multiple cancer types with greater efficacy and tolerability than seen with conventional therapies. FLAG Therapeutics obtained exclusive worldwide rights to the AA/AT and FTAC platforms from Duquesne University in November 2013, including a robust patent estate currently comprised of 26 issued patents and 28 pending applications covering both composition of matter and uses of the compounds.

In the News

FLAG Therapeutics awarded $1,500,000 Phase II SBIR - Development of Novel Targeted Chemotherapeutics for the Treatment of Malignant Pleural Mesothelioma (September 2017)

FLAG Therapeutics awarded $250,000 Small Business Research Loan (SRL) from North Carolina Biotechnology Center (March 2015)

FLAG Therapeutics Awarded $50,000 Company Inception Loan from North Carolina Biotechnology Center
March 20, 2014

A Lifetime of Cancer Research, A Historic Patent Deal
Duquesne University Magazine - Winter 2014

Press Release

Dec 4, 2013 - FLAG Therapeutics Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds